| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
20,430,000 |
| Market
Cap: |
1.36(B) |
| Last
Volume: |
2,387,520 |
Avg
Vol: |
2,380,857 |
| 52
Week Range: |
$37.29 - $69.69 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile ANI Pharmaceuticals is a bio-pharmaceutical company focused on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Co.'s products include: Candesartan Hydrochlorothiazide, Fenofibrate, Fluvoxamine, Hydrocortisone Enema, Lithium Carbonate ER, Mesalamine, Propranolol ER, Terbutaline, and Vancomycin.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
230,132 |
422,694 |
1,171,108 |
1,389,174 |
| Total Sell Value |
$15,188,297 |
$25,482,465 |
$68,628,084 |
$77,001,153 |
| Total People Sold |
8 |
9 |
11 |
11 |
| Total Sell Transactions |
20 |
41 |
78 |
81 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-10-16 |
4 |
AS |
$58.31 |
$761,704 |
I/I |
(13,063) |
1,057,620 |
|
3% |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-10-13 |
4 |
AS |
$57.58 |
$687,332 |
I/I |
(11,937) |
1,070,683 |
|
3% |
|
| Gassert Chad |
SVP - CORP. DEV. & STRATEGY |
• – – |
2023-10-02 |
4 |
AS |
$56.48 |
$1,129,600 |
I/I |
(20,000) |
293,226 |
|
-1% |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-09-19 |
4 |
AS |
$61.23 |
$1,551,140 |
I/I |
(25,333) |
1,082,620 |
|
-10% |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-09-18 |
4 |
AS |
$61.64 |
$519,317 |
I/I |
(8,425) |
1,107,953 |
|
-11% |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-09-15 |
4 |
AS |
$62.81 |
$1,020,160 |
I/I |
(16,242) |
1,116,378 |
|
-13% |
|
| Davis Krista |
SVP, CHIEF HR OFFICER |
• – – |
2023-09-12 |
4 |
D |
$61.91 |
$91,998 |
D/D |
(1,486) |
35,209 |
|
- |
|
| Lalwani Nikhil |
PRESIDENT & CEO |
• • – |
2023-09-08 |
4 |
D |
$61.94 |
$225,833 |
D/D |
(3,646) |
349,744 |
|
- |
|
| Gassert Chad |
SVP - CORP. DEV. & STRATEGY |
• – – |
2023-09-01 |
4 |
AS |
$64.70 |
$1,294,000 |
I/I |
(20,000) |
313,226 |
|
-14% |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-08-29 |
4 |
S |
$63.37 |
$1,584,250 |
I/I |
(25,000) |
1,132,620 |
|
11% |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-08-28 |
4 |
S |
$63.06 |
$1,576,500 |
I/I |
(25,000) |
1,157,620 |
|
10% |
|
| Gutwerg Ori |
SVP, GENERICS |
• – – |
2023-08-23 |
4 |
S |
$62.39 |
$970,851 |
D/D |
(15,561) |
60,915 |
|
10% |
|
| Gutwerg Ori |
SVP, GENERICS |
• – – |
2023-08-23 |
4 |
OE |
$31.49 |
$425,178 |
D/D |
13,502 |
76,476 |
|
- |
|
| Marken James G. |
SVP OPS & PROD DEV |
• – – |
2023-08-23 |
4 |
S |
$63.00 |
$247,716 |
D/D |
(3,932) |
133,112 |
|
10% |
|
| Marken James G. |
SVP OPS & PROD DEV |
• – – |
2023-08-23 |
4 |
OE |
$33.00 |
$207,224 |
D/D |
5,417 |
137,044 |
|
- |
|
| Leonard Matthew J |
Director |
– • – |
2023-08-21 |
4 |
A |
$0.00 |
$0 |
D/D |
7,583 |
7,583 |
|
- |
|
| Brown Robert E. Jr |
10% Owner |
– – • |
2023-08-16 |
4 |
S |
$58.50 |
$11,700,000 |
D/D |
(200,000) |
1,819,259 |
|
10% |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-08-15 |
4 |
AS |
$61.60 |
$1,361,976 |
I/I |
(22,110) |
1,182,620 |
|
-14% |
|
| Lalwani Nikhil |
PRESIDENT & CEO |
• • – |
2023-08-15 |
4 |
S |
$61.13 |
$710,086 |
D/D |
(11,616) |
353,390 |
|
14% |
|
| Lalwani Nikhil |
PRESIDENT & CEO |
• • – |
2023-08-15 |
4 |
OE |
$29.00 |
$336,864 |
D/D |
11,616 |
365,006 |
|
- |
|
| Shanmugam Muthusamy |
HEAD OF R&D, COO-NOVITIUM OPS |
• • – |
2023-08-14 |
4 |
AS |
$61.15 |
$1,705,474 |
I/I |
(27,890) |
1,204,730 |
|
-14% |
|
| Carey Stephen P. |
SVP & CFO |
• – – |
2023-08-14 |
4 |
S |
$61.37 |
$1,082,505 |
D/D |
(17,639) |
155,839 |
|
14% |
|
| Pera Antonio R |
Director |
– • – |
2023-08-14 |
4 |
S |
$60.37 |
$181,110 |
D/D |
(3,000) |
33,627 |
|
14% |
|
| Lalwani Nikhil |
PRESIDENT & CEO |
• • – |
2023-08-11 |
4 |
S |
$57.75 |
$3,272,462 |
D/D |
(56,666) |
353,390 |
|
16% |
|
| Gassert Chad |
SVP - CORP. DEV. & STRATEGY |
• – – |
2023-08-01 |
4 |
AS |
$51.06 |
$1,021,200 |
I/I |
(20,000) |
333,226 |
|
-4% |
|
704 Records found
|
|
Page 4 of 29 |
|
|
0.52 (0.79%) 
